These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874 [TBL] [Abstract][Full Text] [Related]
6. Diet-induced obesity: rodent model for the study of obesity-related disorders. Rosini TC; Silva AS; Moraes Cd Rev Assoc Med Bras (1992); 2012; 58(3):383-7. PubMed ID: 22735233 [TBL] [Abstract][Full Text] [Related]
11. Stressing the importance of choice: Validity of a preclinical free-choice high-caloric diet paradigm to model behavioural, physiological and molecular adaptations during human diet-induced obesity and metabolic dysfunction. Slomp M; Belegri E; Blancas-Velazquez AS; Diepenbroek C; Eggels L; Gumbs MCR; Joshi A; Koekkoek LL; Lamuadni K; Ugur M; Unmehopa UA; la Fleur SE; Mul JD J Neuroendocrinol; 2019 May; 31(5):e12718. PubMed ID: 30958590 [TBL] [Abstract][Full Text] [Related]
12. Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. Alves A; Bassot A; Bulteau AL; Pirola L; Morio B Nutrients; 2019 Jun; 11(6):. PubMed ID: 31208147 [TBL] [Abstract][Full Text] [Related]
13. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467 [TBL] [Abstract][Full Text] [Related]
14. Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Zhang Y; Gu M; Cai W; Yu L; Feng L; Zhang L; Zang Q; Wang Y; Wang D; Chen H; Tong Q; Ji G; Huang C Sci Rep; 2016 Jan; 6():19288. PubMed ID: 26775807 [TBL] [Abstract][Full Text] [Related]
15. Advances in diet-induced rodent models of metabolically acquired peripheral neuropathy. Eid SA; Feldman EL Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34762126 [TBL] [Abstract][Full Text] [Related]
16. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity. Angelini G; Castagneto-Gissey L; Casella-Mariolo J; Caristo ME; Russo MF; Lembo E; Verrastro O; Stefanizzi G; Marini PL; Casella G; Bornstein SR; Rubino F; Mingrone G Am J Physiol Gastrointest Liver Physiol; 2020 Oct; 319(4):G502-G511. PubMed ID: 32812775 [TBL] [Abstract][Full Text] [Related]
17. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis Liu MT; Huang YJ; Zhang TY; Tan LB; Lu XF; Qin J World J Gastroenterol; 2019 Jul; 25(27):3590-3606. PubMed ID: 31367159 [TBL] [Abstract][Full Text] [Related]
18. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789 [TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. Yang S; Kwak S; Lee JH; Kang S; Lee SP PLoS One; 2019; 14(11):e0224626. PubMed ID: 31682638 [TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]